Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants

Pediatric Drugs

Volumn 14, Issue 4, 2012, Pages 233-246

  Pacifici, Gian Maria ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bumetanide; Diuretics; Furosemide; Infants; Neonates; Pharmacokinetics.

Indexed keywords

4 AMINOBUTYRIC ACID; ACETAZOLAMIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIGEN; BISPHOSPHONIC ACID DERIVATIVE; BUMETANIDE; CHLORIDE; CHLOROTHIAZIDE; CORTICOSTEROID; CREATININE; CYSTATIN C; ELECTROLYTE; FUROSEMIDE; IBUPROFEN; INDOMETACIN; POTASSIUM; PROSTAGLANDIN E; SODIUM; THEOPHYLLINE;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; BRONCHOSPASM; CLINICAL PHARMACOLOGY; COLD AIR; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART MALFORMATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DIURESIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; EXTRACORPOREAL OXYGENATION; HUMAN; HYDROCEPHALUS; HYPERCALCEMIA; HYPONATREMIA; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY CALCIFICATION; KIDNEY DEVELOPMENT; LOADING DRUG DOSE; LOW BIRTH WEIGHT; LOW DRUG DOSE; LUNG COMPLIANCE; LUNG DYSPLASIA; LUNG HEMODYNAMICS; LUNG MECHANICS; LUNG VENTILATION; MECONIUM ASPIRATION; NATRIURESIS; NEPHROLITHIASIS; NEPHROTOXICITY; OTOTOXICITY; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; URINE FLOW RATE; URINE VOLUME; VIRAL BRONCHIOLITIS; VITAL SIGN;

ACETAZOLAMIDE; BUMETANIDE; DRUG THERAPY, COMBINATION; DUCTUS ARTERIOSUS, PATENT; EXTRACORPOREAL MEMBRANE OXYGENATION; FUROSEMIDE; HUMANS; HYDROCEPHALUS; HYPERCALCEMIA; IBUPROFEN; INDOMETHACIN; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84862564038     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11596620-000000000-00000     Document Type: Review

References (100)

1. Aperia A, Broberger O, ElinDer G, et al. Postnatal development of renal function in pre-term and full-term infants. Acta Paediatr Scand 1981 70: 183-187
2. Arant Jr BS. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 1978 92: 705-712
3. Eades SK, Christensen ML. The clinical pharmacology of loop diuretics in the pediatric patient. Pediatr Nephrol 1998 12: 603-616
4. Faa G, Gerosa C, Fanni D, et al. Marked interindividual variability in renal maturation of preterm infants: Lessons from autopsy. J Matern Fetal Neonatal Med 2010 23 Suppl. 3: 129-133
5. Leake RD, Trygstad CW, Oh W. Inulin clearance in the newborn infant: Relationship to gestational and postnatal age. Pediatr Res 1976 10: 759-762
6. Mirochnick MH, Miceli JJ, Kramer PA, et al. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 1988 112: 653-657
7. Mirochnick MH, Miceli JJ, Kramer PA, et al. Renal response to furosemide in very low birth weight infants during chronic administration. Dev Pharmacol Ther 1990 15: 1-7
8. Schoemaker RC, Van Der Vorst MM, Van Heel IR, et al. Pediatric Pharmacology Network. Development of an optimal furosemide infusion strategy in infants with modeling and simulation. Clin Pharmacol Ther 2002 72: 383-390
9. Sulyok E, Varga F, Gyö ry E, et al. On the mechanisms of renal sodium handling in newborn infants. Biol Neonate 1980 37: 75-79
10. WitteMK, Stork JE, Blumer JL. Diuretic therapeutics in the pediatric patient. Am J Cardiol 1986 57: 44A-53A
11. Baliga R, Lewy JE. Pathogenesis and treatment of edema. Pediatr Clin North Am 1987 34: 639-648
12. Chennavasin P, Seiwell R, Brater DC, et al. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979 16: 187-195
13. Sjöström PA, Kron BG, Odlind BG. Determinants of furosemide delivery to its site of action. Clin Nephrol 1995 43 Suppl. 1: S38-41
14. Ponto LL, Schoenwald RD. Furosemide (frusemide): A pharmacokinetic/ pharmacodynamic review (part I). Clin Pharmacokinet 1990 18: 381-408
15. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991 41 Suppl. 3: 14-22
16. Tuck S, Morselli P, Broquaire M, et al. Plasma and urinary kinetics of furosemide in newborn infants. J Pediatr 1983 103: 481-485
17. Aranda JV, Perez J, Sitar DS, et al. Pharmacokinetic disposition and protein binding of furosemide in newborn infants. J Pediatr 1978 93: 507-511
18. Aranda JV, Lambert C, Perez J, et al. Metabolism and renal elimination of furosemide in the newborn infant. J Pediatr 1982 101: 777-781
19. Peterson RG, Simmons MA, Rumack BH, et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980 97: 139-143
20. SulliVan JE, Witte MK, Yamashita TS, et al. Pharmacokinetics of bumetanide in critically ill infants. Clin Pharmacol Ther 1996 60: 405-413
21. SulliVan JE, Witte MK, Yamashita TS, et al. Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants. Clin Pharmacol Ther 1996 60: 414-423
22. Vert P, Broquaire M, Legagneur M, et al. Pharmacokinetics of furosemide in neonates. Eur J Clin Pharmacol 1982 22: 39-45
23. Wells TG, Fasules JW, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. J Pediatr 1992 12: 974-980
24. Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease: An update. J Pharmacokinet Biopharm 1989 17: 1-46
25. Young TE, Mangum B. Antimicrobials. In: Neofax: A manual of drugs used in neonatal care. 23rd ed. Montvale (NJ): Thomson Reuters, 2010: 1-99
26. Lopez-Samblas AM, Adams JA, Goldberg RN, et al. The pharmacokinetics of bumetanide in the newborn infant. Biol Neonate 1997 72: 265-272
27. Brater DC. Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics. Fed Proc 1983 42: 1711-3
28. Tuzel IH. Comparison of adverse reactions to bumetanide and furosemide. J Clin Pharmacol 1981 21: 615-619
29. Ramsay LE, McInnes GT, Hettiarachchi J, et al. Bumetanide and frusemide: A comparison of dose-response curves in healthy men. Br J Clin Pharmacol 1978 5: 243-247
30. Asbury MJ, Gatenby PB, O'SulliVan S, et al. Bumetanide: potent new 'loop' diuretic. BMJ 1972 1: 211-213
31. Turmen T, Thom P, Louridas AT, et al. Protein binding and bilirubin displacing properties of bumetanide and furosemide. J Clin Pharmacol 1982 22: 551-556
32. Robertson A, Karp W. Albumin binding of bumetanide. Dev Pharmacol Ther 1986 9: 241-248
33. Ross BS, Pollak A, Oh W. The pharmacologic effects of furosemide therapy in the low-birth-weight infant. J Pediatr 1978 92: 149-152
34. Woo WC, Dupont C, Collinge J, et al. Effects of furosemide in the newborn. Clin Pharmacol Ther 1978 23: 266-271
35. Rane A, Villeneuve JP, Stone WJ, et al. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 1978 24: 199-207
36. Rupp W. Pharmacokinetics and pharmacodynamics of Lasix. Scott Med J 1974 19 Suppl. 1: 5-13
37. Beermann B, Dalén E, Lindström B, et al. On the fate of furosemide in man. Eur J Clin Pharmacol 1975 9: 51-61
38. Beermann B, Dalén E, Lindström B. Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 1977 22: 70-78
39. Calesnick B, Christensen JA, Richter M. Absorption and excretion of furosemide- S35 in human subjects. Proc Soc Exp Biol Med 1966 123: 17-22
40. Hook JB, Williamson HE. Influence of probenecid and alterations in acidbase balance of the saluretic activity of furosemide. J Pharmacol Exp Ther 1965 149: 404-408
41. Prandota J, Houin G. Kinetics of urinary furosemide elimination in infants. Dev Pharmacol Ther 1984 7: 273-284
42. Ward A, Heel RC. Bumetanide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984 28: 426-464
43. Bahrami KR, Van Meurs KP. ECMO for neonatal respiratory failure. Semin Perinatol 2005 29: 15-23
44. Van Der Vorst MM, Wildschut E, Houmes RJ, et al. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care 2006 10: 1-8
45. Van Der Vorst MM, Kist-Van Holthe JE, den Hartigh J, et al. Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery. Br J Clin Pharmacol 2007 64: 796-803
46. Lochan SR, Adeniyi-Jones S, Assadi FK, et al. Coadministration of theophylline enhances diuretic response to furosemide in infants during extracorporeal membrane oxygenation: A randomized controlled pilot study. J Pediatr 1998 133: 86-89
47. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994 45: 1425-1431
48. Kugelman A, Durand M, Garg M. Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Pediatrics 1997 99: 71-75
49. Bar A, Srugo I, Amirav I, et al. Inhaled furosemide in hospitalized infants with viral bronchiolitis: A randomized, double-blind, placebo-controlled pilot study. Pediatr Pulmonol 2008 43: 261-267
50. Pai VB, Nahata MC. Aerosolized furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia in preterm neonates. Ann Pharmacother 2000 34: 386-392
51. Rastogi A, Luayon M, Ajayi OA, et al. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr 1994 125 (6 Pt 1): 976-979
52. Prabhu VG, Keszler M, Dhanireddy R. Pulmonary function changes after nebulised and intravenous frusemide in ventilated premature infants. Arch Dis Child Fetal Neonatal Ed 1997 77: F32-5
53. Ohki Y, Nako Y, Koizumi T, et al. The effect of aerosolized furosemide in infants with chronic lung disease. Acta Paediatr 1997 86: 656-60
54. Gulbis BE, Spencer AP. Efficacy and safety of a furosemide continuous infusion following cardiac surgery. Ann Pharmacother 2006 40: 1797-803
55. Luciani GB, Nichani S, Chang AC, et al. Continuous versus intermittent furosemide infusion in critically ill infants after open heart operations. Ann Thorac Surg 1997 64: 1133-9
56. Reiter PD, Makhlouf R, Stiles AD. Comparison of 6-hour infusion versus bolus furosemide in premature infants. Pharmacotherapy 1998 18: 63-68
57. Van Der Vorst MM, den Hartigh J, Wildschut E, et al. An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation. Crit Care 2007 11: R111
58. Van Der Vorst MM, Ruys-Dudok Van Heel I, Kist-Van Holthe JE, et al. Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery. Intensive Care Med 2001 27: 711-715
59. Lee BS, Byun SY, Chung ML, et al. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. Neonatology 2010 98: 191-199
60. Chevalier RL. Developmental renal physiology of the low birth weight preterm newborn. J Urol 1996 156: 714-719
61. Sulyok E, Varga F, Németh M, et al. Furosemide-induced alterations in the electrolyte status, the function of renin-Angiotensin-Aldosterone system, and the urinary excretion of prostaglandins in newborn infants. Pediatr Res 1980 14: 765-768
62. Friedman Z, Demers LM, Marks KH, et al. Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. J Pediatr 1978 93: 512-515
63. Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Syst Rev 2001 (3): CD001148
64. Andriessen P, Struis NC, Niemarkt H, et al. Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus. Acta Paediatr 2009 98: 797-803
65. Green TP, Thompson TR, Johnson DE, et al. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 1983 31 308: 743-748
66. Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai 2003 86 Suppl. 3: S563-9
67. Borradori C, Fawer CL, Buclin T, et al. Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate 1997 71: 1-10
68. Rybak LP. Pathophysiology of furosemide ototoxicity. J Otolaryngol 1982 11: 127-133
69. Gimpel C, Krause A, Franck P, et al. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int 2010 52: 51-56
70. Downing GJ, Egelhoff JC, Daily DK, et al. Furosemide-related renal calcifications in the premature infant: A longitudinal ultrasonographic study. Pediatr Radiol 1991 21: 563-565
71. Kenney IJ, Aiken CG, Lenney W. Frusemide-induced nephrocalcinosis in very low birth weight infants. Pediatr Radiol 1988 18: 323-325
72. Myracle MR, McGahan JP, Goetzman BW, et al. Ultrasound diagnosis of renal calcification in infants on chronic furosemide therapy. J Clin Ultrasound 1986 14: 281-287
73. Pearse DM, Kaude JV, Williams JL, et al. Sonographic diagnosis of furosemide- induced nephrocalcinosis in newborn infants. J Ultrasound Med 1984 3: 553-556
74. Hufnagle KG, Khan SN, Penn D, et al. Renal calcifications: A complication of long-term furosemide therapy in preterm infants. Pediatrics 1982 70: 360-363
75. Kahle KT, Staley KJ. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures. Neurosurg Focus 2008 25: E22
76. Borgia F, De Pasquale L, Cacace C, et al. Subcutaneous fat necrosis of the newborn: be aware of hypercalcaemia. J Paediatr Child Health 2006 42: 316-318
77. Ghirri P, Bottone U, Coccoli L, et al. Symptomatic hypercalcemia in the first months of life: calcium-regulating hormones and treatment. J Endocrinol Invest 1999 22: 349-353
78. Nair S, Nair SG, Borade A, et al. Hypercalcemia and metastatic calcification in a neonate with subcutaneous fat necrosis. Indian J Pediatr 2009 76: 1155-7
79. Poca MA, Sahuquillo J. Short-term medical management of hydrocephalus. Expert Opin Pharmacother 2005 6: 1525-1538
80. Shinnar S, Gammon K, Bergman Jr EW, et al. Management of hydrocephalus in infancy: use of acetazolamide and furosemide to avoid cerebrospinal fluid shunts. J Pediatr 1985 107 (1): 31-37
81. Prandota J. Clinical pharmacology of furosemide in children: A supplement. Am J Ther 2001 8: 275-289
82. Horinek D, Cihar M, Tichy M. Current methods in the treatment of posthemorrhagic hydrocephalus in infants. Bratisl Lek Listy 2003 104: 347-351
83. Whitelaw A, Kennedy CR, Brion LP. Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation. Cochrane Database Syst Rev 2001 (2): CD002270
84. Kennedy CR, Ayers S, Campbell MJ, et al. Randomized, controlled trial of acetazolamide and furosemide in posthemorrhagic ventricular dilation in infancy: follow-up at 1 year. Pediatrics 2001 108: 597-607
85. Libenson MH, Kaye EM, Rosman NP, et al. Acetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn. Pediatr Neurol 1999 20: 185-191
86. Gaskill SJ, Marlin AE, Rivera S. The subcutaneous ventricular reservoir: An effective treatment for posthemorrhagic hydrocephalus. Childs Nerv Syst 1988 4: 291-295
87. Pacifici GM, Rane A. Distribution of UDP-glucuronyltransferase in different human foetal tissues. Br J Clin Pharmacol 1982 13: 732-735
88. Pacifici GM, Sawe J, Kager L, et al. Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol 1982 22: 553-558
89. Cappiello M, Giuliani L, Rane A, et al. 5'-Diphosphoglucuronic acid (UDPGA) in the human fetal liver, kidney and placenta. Eur J Drug Metab Pharmacokin 2000 25: 161-163
90. Burg M, Stoner L, Cardinal J, et al. Furosemide effect on isolated perfused tubules. Am J Physiol 1973 225: 119-124
91. Martin SJ, Danziger LH. Continuous infusion of loop diuretics in the critically ill: A review of the literature. Crit Care Med 1994 22: 1323-9
92. Pivac N, Rumboldt Z, Sardelić S, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res 1998 18: 121-128
93. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med 1997 25: 1969-1975
94. Ad N, SuyDerhoud JP, Kim YD, et al. Benefits of prophylactic continuous infusion of furosemide after the maze procedure for atrial fibrillation. J Thorac Cardiovasc Surg 2002 123: 232-236
95. MojtahedzadehM, Salehifar E, Vazin A, et al. Comparison of hemodynamic and biochemical effects of furosemide by continuous infusion and intermittent bolus in critically ill patients. J Infus Nurs 2004 27: 255-261
96. Klinge JM, Scharf J, Hofbeck M, et al. Intermittent administration of furosemide versus continuous infusion in the postoperative management of children following open heart surgery. Intensive Care Med 1997 23: 693-697
97. Singh NC, Kissoon N, al Mofada S, et al. Comparison of continuous versus intermittent furosemide administration in postoperative pediatric cardiac patients. Crit Care Med 1992 20: 17-21
98. Bartlett RH, Gazzaniga AB, Jefferies MR, et al. Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. Trans Am Soc Artif Intern Organs 1976 22: 80-93
99. Kim ES, Stolar CJ. ECMO in the newborn. Am J Perinatol 2000 17: 345-356
100. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003 42: 403-417